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Abstract
Background: Around 35–45 % of people in contact with services for a first episode of psychosis are using cannabis.
Cannabis use is associated with delays in remission, poorer clinical outcomes, significant increases in the risk of relapse,
and lower engagement in work or education. While there is a clear need for effective interventions, so far only very
limited benefits have been achieved from psychological interventions. Contingency management (CM) is a behavioural
intervention in which specified desired behavioural change is reinforced through financial rewards. CM is now
recognised to have a substantial evidence base in some contexts and its adoption in the UK is advocated by the
National Institute for Health and Care Excellence (NICE) guidance as a treatment for substance or alcohol misuse.
However, there is currently little published data testing its effectiveness for reducing cannabis use in early psychosis.
Methods: CIRCLE is a two-arm, rater-blinded randomised controlled trial (RCT) investigating the clinical and cost-
effectiveness of a CM intervention for reducing cannabis use among young people receiving treatment from UK Early
Intervention in Psychosis (EIP) services. EIP service users (n = 544) with a recent history of cannabis use will be recruited.
The experimental group will receive 12 once-weekly CM sessions, and a voucher reward if urinalysis shows that they have
not used cannabis in the previous week. Both the experimental and the control groups will be offered an Optimised
Treatment as Usual (OTAU) psychoeducational package targeting cannabis use. Assessment interviews will be performed
at consent, at 3 months, and at 18 months. The primary outcome is time to relapse, defined as admission to an acute
mental health service. Secondary outcomes include proportion of cannabis-free urine samples during the intervention
period, severity of positive psychotic symptoms, quality-adjusted life years, and engagement in work or education.
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Discussion: CIRCLE is a RCT of CM for cannabis use in young people with a recent history of psychosis (EIP service users)
and recent cannabis use. It is designed to investigate whether the intervention is a clinically and cost-effective treatment
for cannabis use. It is intended to inform future treatment delivery, particularly in EIP settings.
Trial registration: ISRCTN33576045: doi 10.1186/ISRCTN33576045, registered on 28 November 2011.
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Background
Cannabis is the most commonly used drug among people
with psychosis, with rates of current use around the time
of the onset of psychosis regularly recorded as between 35
and 45 %, well above use patterns in same-age, nonpsy-
chotic populations [1, 2]. Continued use following the on-
set of psychosis is associated with poorer individual
outcomes and greater societal burdens. Hazards include
delays in remission, suicidal behaviour, violence and home-
lessness [1, 3, 4]. In prospective investigations in first-
episode psychosis, cannabis use is associated with markedly
higher relapse rates: an Australian study reported a 51 %
relapse rate over 15-month follow-up among substance
users (mostly cannabis) compared with 17 % among nonu-
sers [5], accompanied by a threefold difference in inpatient
admission rates. Similarly, a Dutch study reported a 42 %
relapse rate among persistent cannabis users compared
with 17 % among those who never used or stopped round
the time of first onset [3]. A dose-response relationship be-
tween severity of cannabis misuse and time to relapse was
also reported in this study. Studies of comorbid substance
misuse among people with established psychosis indicate
that people who persist in problematic drug use are heavy
users of acute mental health services, are more likely than
others with psychotic illnesses to engage in acts of violence,
and are less likely to work, sometimes using disability ben-
efits to sustain drug use [6–8]. Thus, if a reduction in can-
nabis use can be achieved very early in the course of a
psychotic illness, this has potential to improve the life ex-
periences and social recovery of young people who develop
psychosis, and to reduce the burden on carers, on mental
health, criminal justice and welfare services and on the
wider society over many years. This is the overall aim of
the current study.
Systematic reviews find that the evidence on effective in-
terventions for comorbid substance misuse in established
psychosis is very limited [9, 10]. Despite a promising pilot
study [11], a large MRC-funded trial, the MIDAS study, has
shown no effect on primary or secondary outcomes from a
relatively lengthy intervention (29 sessions over 9 months)
consisting of motivational interviewing (MI) and cognitive
behavioural therapy (CBT). The difficulties in intervening
effectively in established psychosis suggest that it may be
fruitful to target an earlier stage of illness, when several re-
cent studies indicate that patterns of use are in a state of
substantial flux [12, 13]. Many people are ambivalent about
persisting with use and have substantial motivation for
change, though some who initially abstain soon return to
use [14]. This contrasts with the very limited motivation for
change found in established psychosis [15], so that early
psychosis may well be a stage at which achieving change
with a relatively brief intervention is more feasible. How-
ever, in a similar study [16] to the MIDAS trial, a MI and
CBT intervention was trialled for cannabis in Early Inter-
vention In Psychosis (EIP) service users, also over 9 months
(24 sessions), and again found no benefit for the interven-
tion compared to treatment as usual.
The very limited benefits achieved from psychological in-
terventions, such as MI and CBT in comorbid substance
misuse in psychosis, have made us look elsewhere for a po-
tentially effective intervention. Contingency management
(CM) is an approach that involves offering rewards contin-
gent on engagement in substance use treatment and on evi-
dence of abstinence. CM is now recognised to have a
strong evidence base supporting the efficacy of the inter-
vention in a range of contexts, such as smoking cessation
[17] and substance misuse disorders [18], and its adoption
in the UK is advocated in guidance issued by the National
Institute for Health and Care Excellence (NICE) [19]. How-
ever, with the exception of a small number of recently
evaluative studies in Europe [20], the evidence base is
drawn almost entirely from the US. There is relatively little
UK experience of using CM, with only a few evaluations of
CM reported. Recent examples include the CONMAN
trial, which provided an evidence base for CM in the uptake
of hepatitis B vaccines among opiate users [21], and FIAT,
which found incentives to be effective for reinforcing adher-
ence to antipsychotic medication [22]. The NICE review of
psychosocial interventions [19] identified 14 trials of CM,
all from the US, that met criteria for inclusion, of which
three involved cannabis use. A consistent finding of a bene-
fit for CM was reported, with most studies using abstinence
at 12 weeks as their outcome measure.
Just one North American CM study has so far been re-
ported among people with comorbid substance misuse
and psychosis; the substances included were cocaine,
heroin, and cannabis. This was unusual among treat-
ment studies in this population in finding a positive ef-
fect. Bellack et al. [23] reported that CM, combined with
a psychological intervention, resulted in more drug-free
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urine samples than an enhanced treatment as usual
intervention (Supportive Treatment for Addiction Re-
covery), and in reduced hospitalisation, and a better
quality of life. However, only a small proportion of par-
ticipants abused cannabis (7 %) with 93 % abusing co-
caine or heroin. Sigmon et al. [24, 25] performed two
small feasibility studies using a within-subjects reversal
design that also reported a beneficial effect from the
intervention. We find no other evidence of CM studies
for cannabis use in a population with psychosis.
In the present study, we will investigate the clinical
and cost-effectiveness of CM for reducing cannabis use
among EIP service users. This will be evaluated in terms
of clinical service use, the presence of psychotic symp-
toms, cannabis use, and health economic measures. The
primary outcome will be whether CM improves time to
relapse, measured as admission to acute mental health
services, compared to recommended standard care.
Methods/design
Design
CIRCLE is a rater-blind, randomised controlled trial with
two arms (Fig. 1). The experimental group will receive a
12-week CM intervention, as well as a manualised psy-
choeducational intervention delivered by clinical staff,
which represents an Optimised version of Treatment as
Usual (OTAU) that is offered by EIPs in the management
of cannabis misuse. The control group will receive OTAU
only. Assessments will be performed at the time of con-
sent, 12 weeks following consent (at the end of the inter-
vention period), and at 18 months following consent. The
primary outcome is time to relapse, operationalised as
admission to an acute mental health service.
Recruitment
Recruitment to the trial will be in EIP services throughout
the Midlands and the South East of England. Participants
will be on the caseload of an EIP service and aged 18–36.
Other inclusion/exclusion criteria are listed below.
Group allocation
Following pretrial assessments, consenting clients will be
randomised to group, stratified on severity of cannabis
use (one to three uses per week, more than three uses
per week). A remote, impartial randomisation service
will manage the allocation to groups coordinated by the
PRIMENT Clinical Trials Unit based at University
College London (UCL).
Trial assessors
Outcome assessments will be performed by trial re-
search staff. Primary outcome assessors will be blinded
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram. Showing flow of participants through the trial
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to randomised allocation. Secondary outcome assessors
will be blinded at the 18-month assessment interview.
Research staff will be trained in the use of all measures
by members of the CIRCLE team. Joint ratings with one
another and with senior members of the team supervis-
ing them will be used to establish reliability.
Interventions
The OTAU package will provide the context in which we
will test the impact of a CM intervention. The CM inter-
vention will involve the offer of voucher rewards for
cannabis-free urine samples over a 12-week period to
recent cannabis users with first-episode psychosis (defined
below). We will first describe OTAU, delivered to both
experimental and control groups, and then the CM
intervention to be received by the experimental group only.
Optimised Treatment as Usual (Psychoeducational package)
To be confident that we are measuring the effects of CM, a
psychoeducational intervention will be delivered to both ex-
perimental and control groups. Guidelines on EIP care rec-
ommend that psychoeducational interventions for cannabis
should be an important component of routine care, but
consultations with EIP managers and staff suggest that the
extent to which this is realised in practice is very variable
between services and individual clinical staff. Our aim is
thus to create a standardised version to be delivered by staff
working in EIPs recruiting to the trial. A training manual
for delivering the package, and supporting materials will be
provided by trial staff to clinicians delivering OTAU. The
intervention is designed to be sufficiently highly structured
for staff without high-level clinical qualifications, such as
support workers or assistant psychologists, to be able to de-
liver it competently following brief training.
OTAU has been designed to be an individually tailored
psychoeducational approach to cannabis use for generic
EIP clinicians, which applies general psychoeducational ap-
proaches used in first-episode psychosis [26]. It draws on
the psychoeducational package offered in the control arm
of a previous Melbourne pilot study of psychological inter-
vention for cannabis use, the Cannabis and Psychosis
(CAP) trial [27]. The package is comprised of six modules
to be delivered via a standard PC. Full delivery of all six
modules is typically achieved over approximately 3 h, nor-
mally offered over six regularly programmed sessions of
30 min duration. The package includes a pdf, video mater-
ial, short quizzes, audio files, and further information and
written records of the modules for the service user to keep.
The material will remain focused on providing information
in accordance with psychoeducation procedures, and will
not act as a psychological intervention. The clinician’s main
aim is harm minimisation, with an acknowledgement that
in a young person with psychosis, cannabis abstinence may
be required to ensure that no harm is done. The content is
based on MI principles, relapse prevention, and harm-
reduction strategies.
Psychoeducational materials including video, written,
and web-based materials will present current information
on the potential advantages and disadvantages of cannabis
use and of cannabis abstinence. To help the participant to
make an informed decision about continued use, the EIP
staff will discuss the positives and negatives of cannabis
use by exploring its impact on seven areas: family, finance,
activity/engagement in work or education, mental health,
physical health, legality, and social groups/friendships. Fi-
nally, staff will discuss setting goals regarding the young
person’s future use of cannabis in the context of harm
minimisation, as well as strategies for achieving their goals
and avoiding relapse into patterns of cannabis use that
compromise those goals.
Contingency management
The CM intervention offers financial incentives contingent
on urinalysis results indicating cannabis abstinence. The
intervention voucher schedule and rules are adapted from
Budney et al. [28, 29], which offered a voucher-based CM
intervention for treatment of cannabis dependence in the
general population. The intervention comprises 12 once-
weekly urinalysis sessions and will be delivered by EIP clini-
cians. At each session, the participant will be required to
provide a urine sample. A temperature strip on the side of
the specimen cup will allow the EIP staff to check whether
the sample has been tampered with. In week 1 of the inter-
vention, details of the intervention will be explained to the
participant, and they will be asked to sign an ‘abstinence
contract’ indicating that they understand and accept its
rules, and agree to abide by the test results. In the first
week, participants will receive a £5 voucher for attending
and providing a urine specimen independent of the drug
test results, which provides a ‘baseline’ result. From week 2
to week 12, participants will receive vouchers, increasing by
£5 every 2 weeks, contingent upon producing negative
specimens. Vouchers will be for a local supermarket. Partic-
ipants who abstain from cannabis use for the full duration
of the intervention will earn £240.
Urinalysis will be performed using a small benchtop ana-
lyser capable of providing rapid test results of drug misuse
urinary concentration (Kaiwood CHR-110). To perform the
analysis, the EIP staff member pipettes a fixed amount of
urine into a buffer solution tube to give a 7:1 serial dilution.
This allows a standard 50-ng/ml marijuana test cassette
placed in the analyser to provide a urinary cannabis con-
centration reading between 0 and 350 ng/ml. Guidelines
will be provided to the EIP staff to allow interpretation of
the test results, whereby a sufficient drop in urinary tetra-
hydrocannabinol (THC) concentration will be taken as in-
dicative of abstinence since the previous urinalysis session.
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These guidelines are based on published data regarding the
urinary half-life of cannabis [30].
Participants are able to prearrange missing scheduled
sessions (‘holiday week’) and still receive the reward for
that week if they have a valid commitment that prevents
them from attending. They can do this on a maximum of
two occasions for 1 week only each time. They will still be
expected to show evidence of abstinence at the following
session to receive a reward for the holiday week. If the
participant misses the following week or provides a posi-
tive sample, no financial incentive will be received for the
holiday week. Holiday weeks need to be arranged with the
staff member performing the intervention no later than at
the time of the previous scheduled appointment. The
intervention will be suspended for a maximum of 1 month
if a participant relapses or otherwise loses mental capacity.
If capacity is not regained in 1 month, the intervention
will not continue. If a participant fails to attend on mul-
tiple consecutive weeks, or if contact is lost with the par-
ticipant entirely, each missed week will be counted as a
failure to attend.
Failure to attend intervention sessions, specimens sug-
gesting cannabis use, or failure to submit a scheduled
specimen will reset the value of vouchers back to the
initial £5.00. If the participant attends the next week and
provides a negative sample, they will be rewarded with
£10. In the subsequent week, if the participant provides
a second negative sample voucher values will continue
from the highest previous level of reward.
Selection and training of staff
Staff in the EIP services will deliver the CM and OTAU
interventions. Training will be delivered to all staff deliv-
ering the interventions by members of the research team
over a period of half a day on average.
Inclusion/exclusion criteria
Inclusion criteria
The cohort will be EIP service users who have recently
abused cannabis. Recent cannabis use is operationalised
as having used cannabis at least once during 12 of the
previous 24 weeks. Additional eligibility criteria include
(1) being aged 18–36, (2) having stable accommodation
(i.e. not street homeless or roofless), (3) speaking enough
English to be able to understand fully and answer the as-
sessment instruments, and (4) being able to give in-
formed consent. EIP teams have been set up across
England following the 2000 NHS Plan [31]. Standard cri-
teria for EIP include developing symptoms of psychotic
illness for the first time, with positive psychotic symp-
toms persisting for at least a week and accompanied by
evidence of significant risk and/or functional decline.
Service users are typically discharged after 3 years on
the caseload of an EIP team.
Exclusion criteria
Exclusion criteria include (1) those who fail EIP service
inclusion criteria, (2) those currently engaged in treat-
ment for cannabis use with another agency, (3) those
currently compulsorily detained in hospital or prison, or
(4) those on probation or Community Treatment Order
requiring drug testing for cannabis.
Obtaining informed consent
In the first instance, a member of the EIP staff will obtain
agreement from potential participants to being contacted
by a member of the CIRCLE research team. The re-
searcher will then meet with the service user to provide a
participant information sheet, written in plain English,
which will explain all aspects of the study. They will also
explain all benefits of the study and known risks. The
service user will be given at least 48 h to consider partici-
pation prior to consent being taken.
Ethical approval
Ethical approval for the trial was received on 16 March
2012 from the London – South East NRES Committee
(REC reference 11/LO/1939). Written informed consent
will be obtained from all participants in the trial. The
original consent forms will be stored at the author’s in-
stitutions (UCL, KCL, University of Sussex, and War-
wick University), and a copy will be kept in the patients’
clinical notes.
Assessment interviews
Participants will be given three assessment interviews: at
the time of consent, at 12 weeks following consent, and
at 18 months following consent, a time at which a sig-
nificant proportion of young persons with psychosis will
relapse if they are going to do so [32, 33]. All partici-
pants will be given a £20 voucher for their time, and at
the follow-up assessment all participants will be given an
extra £10 for the provision of a urine sample. At
18 months, the primary outcome and some secondary
outcome data will also be collected from electronic pa-
tient records.
Outcome measures
At all assessment interviews the following measures will
be performed in addition to the collection of standard
demographic information (Fig. 2):
 Cannabis use
○ The Time Line Follow Back (TLFB) [34] will be
used to record self-reported cannabis use over
the last 6 months. The TLFB is a retrospective
calendar-based measure of daily substance use,
with good test-retest reliability demonstrated
for cannabis [35]. This will be used to establish
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eligibility in terms of cannabis use and extent
of recent use
○ Structured Clinical Interview for the Diagnostic
and Statistical Manual of Mental Disorders,
version 4 (DSM-IV) (SCID) part E will be used
to assess history of alcohol and substance
misuse disorders
○ Specimens for urinalysis will be obtained with
the threshold set at a level for detecting
cannabis use in the previous 28 days (i.e.
50 ng/ml cannabis metabolites)
 Psychotic symptoms
○ The positive and negative subscales of the
Positive and Negative Syndrome Scale (PANSS)
[36]. The PANSS is a well-established measure
of psychotic symptoms, with strong psycho-
metric properties in terms of validity, reliability,
and sensitivity [37]
 Service use and health economic analysis
○ Client Service Receipt Inventory (CSRI),
developed originally by Beecham and Knapp
[38] will be used to record clinical service use,
medication use, receipt of state welfare, and use
of other state-funded services including
criminal justice services
○ The 12-Item Short Form Survey (SF-12) [39]
and the EuroQoL, 5 dimensions (EQ-5D)
questionnaire [40] are widely used measures of
health status with good psychometric proper-
ties [41, 42], which will be used to derive
quality-adjusted life years’ (QALYs) data
Primary outcome
The primary outcome will be time to relapse. Admission to
a psychiatric hospital, crisis resolution team or crisis house,
or other acute mental health service will be used as a
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT** -t1 0
Week 
1
Week 
2
Week 
3
Week
…
Week 
12 18 months
ENROLMENT:
Eligibility screened X
Informed consent X
Allocation X
INTERVENTIONS:
CM – Experimental 
group only
OTAU –
experimental and 
control groups
X X X
ASSESSMENTS:
Demographics 
X X X
EQ-5D
X X X
PANSS
X X X
SF-12
X X X
SCID (Part E)
X X X
CSRI
X X X
TLFB
X X X
Urinalysis for 
cannabis (not part 
of CM intervention)
X X X
Acute admissions
data recorded from 
patient notes
X
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure. Overview of the schedule of events
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marker of relapse. The primary outcome will be assessed at
18-month follow-up based on electronic patient records.
Dates of admission will be recorded and participants will be
followed until they have relapsed, are lost to follow-up, or
until the end of the 18-month study period.
Secondary outcomes
Secondary outcomes will be collected mainly through
assessment interview, and will include:
 Cannabis use, including self-reported use and
urinalysis results at follow-up
 Positive symptom severity (Positive and Negative
Syndrome Scale [36])
 Social functioning, based on self-reports of en-
gagement in work or study
 Number of days cannabis use in the previous
12 weeks (for 12-week follow-up) or 6 months (for
18-month follow-up)
 Number of admissions over 18 months’ follow-up
 QALYs (SF-12 and EQ-5D) [43] and service use
(CSRI) will be used in the cost-effectiveness analyses,
as described in the analysis section below. Service
utilisation data will be augmented where possible
from participants’ medical records at 18 months
Proposed sample size
Our sample size for the main trial is based on data sug-
gesting a usual relapse rate of around 50 % over the
study timeframe in cannabis users [3, 5]. A 15 % de-
crease in this relapse rate due to the intervention is clin-
ically beneficial. Using a power of 90 % and a
significance level of 5 %, a total sample size of 460 sub-
jects will be required. This sample size is based on an
analysis of time to relapse and will allow us to detect a
37 % decrease in the hazard of relapse (hazard ratio of
0.63) in the intervention group using a Cox proportional
hazards model. This sample size has been calculated
using Stata version 11 [44]. The sample size is inflated
by a factor of 1.06; assuming that each person delivering
the intervention sees an average of four service user par-
ticipants in the trial, and an intraclass correlation coeffi-
cient of 0.02 for clinician clustering, this gives a total
sample size of 488. Finally, the sample size is inflated by
10 % to account for attrition for the primary outcome,
giving a total sample size of 544.
Statistical analysis
A detailed analysis plan will be written and signed off by
the Data Monitoring and Ethics Committee for the trial
before the analysis commences. Initial analyses will look
at summary statistics for all variables, both overall and
by randomised group. Summary statistics for continuous
variables will be mean, median, standard deviation (SD),
lower quartile, upper quartile, and minimum and max-
imum and will be reported appropriately according to
distribution. Summary statistics for categorical variables
will be frequency and percentage within each category.
Summary statistics of baseline variables by whether a par-
ticipant has dropped out of the study will also be examined
to determine whether the dropouts had similar characteris-
tics to those who remained in the study at baseline.
After checking the assumptions of proportional haz-
ards, Cox proportional hazards modelling to compare
the intervention and control groups, adjusting for sever-
ity of cannabis use at baseline (dichotomous – one to
three times a week versus four or more times a week),
will be carried out for the primary outcome. Robust
standard errors will be used to account for clustering by
care coordinator. If the assumption of proportional haz-
ards is not fulfilled, alternative modelling strategies will
be employed. The secondary outcomes will be analysed
using appropriate regression models, separately for data
collected at 12 weeks and 18 months. Estimates and
95 % confidence intervals will be presented for the sec-
ondary outcomes. In a supportive analysis, all analyses
will be adjusted for an indicator as to whether or not the
participant was in the pilot trial and for potential base-
line predictors of missingness related to outcome. All
analyses will be carried out on an intention-to-treat basis
using all available data.
Missing data
It is expected that there will be few missing data for the pri-
mary outcome as data for this will be extracted from the
participants’ medical records. There is likely to be more
missing data for the secondary outcomes as the majority re-
quire the participant to be interviewed to complete the
measures. For both the primary and secondary outcomes
we will check the extent and patterns of missing data and
identify predictors of missingness. Multiple imputation or
adjustment for potential predictors of missingness related
to the outcome will be performed if appropriate.
Economic evaluation
For the health economic analysis, intervention costs will
be calculated using available data on staff costs, incen-
tives, on-costs, other overheads, and activity levels.
These will be added to the costs of other health and so-
cial care services derived from the Client Service Receipt
Inventory and records combined with nationally applic-
able unit costs (e.g. Curtis [45]). Cost comparisons at 3
and 18 months will be made using regression models,
with bootstrap methods used to generate confidence in-
tervals around the cost differences. Cost-effectiveness
from an NHS perspective at 3 and 18 months will use
three outcome measures: number of cannabis-negative
urine samples, days of reported cannabis abstinence and
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QALYs (derived from the EQ-5D with SF-12 QALYs
used in secondary analyses)). If, for any of these the
intervention has higher costs and better outcomes than
usual treatment, then cost-effectiveness will be expressed
in the form of incremental cost-effectiveness ratios, esti-
mated by dividing the incremental costs by the incre-
mental benefits of the intervention. Uncertainty around
cost-effectiveness estimates will be explored using cost-
effectiveness planes (through generating a large number
of cost-outcome combinations using bootstrap methods)
and cost-effectiveness acceptability curves (showing the
probability of the intervention being cost-effective at
various levels of willingness to pay for health benefits).
The range of values for QALYs will be £0 to £100,000 so
as to include the threshold used by NICE. The values for
the other measures will be chosen so that the points at
which one arm has 50 %, 60 %, 70 %, 80 %, and 90 % of
being the most cost-effective can be observed. It will
then be a value judgement as to whether these values
are acceptable. Cost-effectiveness will be investigated re-
gardless of clinical outcome.
Discussion
The present study is a rater-blinded RCT investigating
the clinical and cost-effectiveness of CM for reducing
cannabis use in EIP patients with a history of recent
cannabis use. Cannabis is a significant issue in this
population. Rates of cannabis use among people with
first-episode psychosis are high, resulting in poorer clin-
ical, social, and functional outcomes, and greater clinical
service use. However, there is little evidence for any ef-
fective interventions for comorbid substance misuse in
established psychosis. If CM is found to be clinically and
economically beneficial, it will offer strong support for
using such interventions to reduce cannabis use among
EIP service users.
Strengths and limitations
With a recruitment target of 544 participants, CIR-
CLE is one of the largest trials of CM worldwide. To
the best of our knowledge it is also the first RCT of
CM specifically for cannabis use in psychosis, al-
though there are a number of related studies. Bellack
et al. [23] trialled CM for substance use in psychosis,
including cannabis, cocaine, or heroin, which required
participants to test negative from the first session.
Sigmon et al. [24, 25] performed two small feasibility
studies of CM for cannabis use in psychosis, but used
within-subject designs rather than a RCT design. Par-
ticipants are followed over a relatively long period of
18 months in accordance with NICE recommenda-
tions for future research for psychosocial interven-
tions for substance misuse in psychosis [46]. The
rationale for targeting EIP patients in particular is
that there is also good reason to believe that motiv-
ation to change patterns of cannabis and other sub-
stance use is high in this cohort [15]. Secondly, EIP
is a form of secondary preventative care [47], with
the aim of preventing or attenuating the risk of re-
lapse to improve long-term prognosis. Given the sub-
stantial evidence base linking cannabis use to higher
rates of relapse, reducing cannabis use in EIP services
is consistent with EIP aims.
One potential concern regarding the use of CM inter-
ventions in publicly funded health services is its accept-
ability to the public, clinicians, and service users. A
mixed-method substudy to the main trial to explore this
topic is planned. However, there is already some evi-
dence that public opinion is in favour of CM for treat-
ment adherence in severe mental illness [48]. Potential
concerns about the use of financial incentives were also
carefully considered in the design of the CIRCLE inter-
vention. The design is based on Budney et al. [28, 29]
and feedback on it was sought from service users, pilot
study participants, carers, and clinical teams before and
after the pilot study through focus groups and one-to-
one interviews.
One technical issue for CM for cannabis use is the
relatively long effective half-life of cannabis. Conven-
tional marijuana urinalysis tests could not be used for
the CM, as a positive urine result may be related to
cannabis use that had taken place more than 1 week
previously. Use of such tests would delay the initi-
ation of treatment by up to 4 weeks to allow a partic-
ipant’s urinary THC level to fall below 50 ng/ml. To
address this, CIRCLE uses desktop analysers capable
of providing a urinary THC concentration reading. As
discussed, a reduction in urinary THC in line with
trial guidelines will be taken as evidence of abstin-
ence. However, it is possible that a reduction in urin-
ary THC over a 1-week period could occur due to a
reduction in cannabis use rather than abstinence. As
such, it is possible that participants can receive the
voucher reward while still using in the short term.
However, medium and long-term trends, detectable
over two or three sessions, will clearly indicate abstin-
ence rather than reduction of cannabis use as urinary
THC will not continue to decline or fall to below
50 ng/ml. Participants will be informed that they will
need to abstain fully throughout the intervention
period to receive all the voucher rewards.
Trial status
The pilot phase of CIRCLE began on 1 January 2012 and
ended on 28 February 2013. Approval to proceed to the
full trial was received in April 2013 and recruitment to
the main trial is currently ongoing. The end date for
CIRCLE is 31 October 2017.
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